Minocycline protects SH-SY5Y cells from 6-hydroxydopamine by inhibiting both caspase-dependent and -independent programmed cell death

Journal of Neuroscience Research

Volumn 90, Issue 3, 2012, Pages 682-690

  Ossola, Bernardino ^a   Lantto, Tiina A ^a   Puttonen, Katja A ^b   Tuominen, Raimo K ^a   Raasmaja, Atso ^a   Männistö, Pekka T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Apoptosis; Neurodegeneration; Neuroprotection; Paraptosis; Parkinson's disease

Indexed keywords

CASPASE 3; LACTATE DEHYDROGENASE; MINOCYCLINE; OXIDOPAMINE;

APOPTOSIS; ARTICLE; CELL VIABILITY; CHROMATIN CONDENSATION; CONTROLLED STUDY; DNA FRAGMENTATION; DOPAMINERGIC NERVE CELL; DRUG INHIBITION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NEUROPROTECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

ANTI-BACTERIAL AGENTS; APOPTOSIS; CASPASE 3; CELL LINE; CELLS, CULTURED; DNA FRAGMENTATION; HUMANS; MINOCYCLINE; NEURONS; OXIDOPAMINE;

EID: 84855871615     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22791     Document Type: Article

References (42)

1. Alano CC, Kauppinen TM, Valls AV, Swanson RA. 2006. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci U S A 103: 9685-9690.
2. Asare N, Landvik NE, Lagadic-Gossmann D, Rissel M, Tekpli X, Ask K, Lag M, Holme JA. 2008. 1-Nitropyrene (1-NP) induces apoptosis and apparently a non-apoptotic programmed cell death (paraptosis) in Hepa1c1c7 cells. Toxicol Appl Pharmacol 230: 175-186.
3. Bonilla E, Medina-Leendertz S, Villalobos V, Molero L, Bohorquez A. 2006. Paraquat-induced oxidative stress in drosophila melanogaster: effects of melatonin, glutathione, serotonin, minocycline, lipoic acid and ascorbic acid. Neurochem Res 31: 1425-1432.
4. Bröker LE, Kruyt FA, Giaccone G. 2005. Cell death independent of caspases: a review. Clin Cancer Res 11: 3155-3162.
5. Casarejos MJ, Menendez J, Solano RM, Rodriguez-Navarro JA, Garcia de Yebenes J, Mena MA. 2006. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J Neurochem 97: 934-946.
6. Cornet S, Spinnewyn B, Delaflotte S, Charnet C, Roubert V, Favre C, Hider H, Chabrier PE, Auguet M. 2004. Lack of evidence of direct mitochondrial involvement in the neuroprotective effect of minocycline. Eur J Pharmacol 505: 111-119.
7. Diguet E, Fernagut PO, Wei X, Du Y, Rouland R, Gross C, Bezard E, Tison F. 2004. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur J Neurosci 19: 3266-3276.
8. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP, Paul SM. 2001. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A 98: 14669-14674.
9. Fernandez-Gomez FJ, Galindo MF, Gomez-Lazaro M, Gonzalez-Garcia C, Cena V, Aguirre N, Jordan J. 2005. Involvement of mitochondrial potential and calcium buffering capacity in minocycline cytoprotective actions. Neuroscience 133: 959-967.
10. Furukawa K, Estus S, Fu W, Mark RJ, Mattson MP. 1997. Neuroprotective action of cycloheximide involves induction of bcl-2 and antioxidant pathways. J Cell Biol 136: 1137-1149.
11. Good ML, Hussey DL. 2003. Minocycline: stain devil? Br J Dermatol 149: 237-239.
12. Goulden V, Glass D, Cunliffe WJ. 1996. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 134: 693-695.
13. He Y, Appel S, Le W. 2001. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 909: 187-193.
14. Jordan J, Fernandez-Gomez FJ, Ramos M, Ikuta I, Aguirre N, Galindo MF. 2007. Minocycline and cytoprotection: shedding new light on a shadowy controversy. Curr Drug Deliv 4: 225-231.
15. Kääriäinen TM, Piltonen M, Ossola B, Kekki H, Lehtonen S, Nenonen T, Lecklin A, Raasmaja A, Männistö PT. 2008. Lack of robust protective effect of quercetin in two types of 6-hydroxydopamine-induced parkinsonian models in rats and dopaminergic cell cultures. Brain Res 1203: 149-159.
16. Kroemer G, Jäättelä M. 2005. Lysosomes and autophagy in cell death control. Nat Rev Cancer 5: 886-897.
17. Kupsch K, Hertel S, Kreutzmann P, Wolf G, Wallesch CW, Siemen D, Schonfeld P. 2009. Impairment of mitochondrial function by minocycline. FEBS J 276: 1729-1738.
18. Lin S, Wei X, Xu Y, Yan C, Dodel R, Zhang Y, Liu J, Klaunig JE, Farlow M, Du Y. 2003. Minocycline blocks 6-hydroxydopamine-induced neurotoxicity and free radical production in rat cerebellar granule neurons. Life Sci 72: 1635-1641.
19. Macdonald H, Kelly RG, Allen ES, Noble JF, Kanegis LA. 1973. Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther 14: 852-861.
20. Mañáková S, Puttonen KA, Raasmaja A, Männistö PT. 2003. Ara-C induces apoptosis in monkey fibroblast cells. Toxicol In Vitro 17: 367-373.
21. Mañáková S, Puttonen KA, Raasmaja A, Männistö PT. 2004. The roles of dopamine transporter and Bcl-2 protein in the protection of CV1-P cells from 6-OHDA-induced toxicity. Toxicol Lett 154: 117-123.
22. Mansson R, Hansson MJ, Morota S, Uchino H, Ekdahl CT, Elmer E. 2007. Re-evaluation of mitochondrial permeability transition as a primary neuroprotective target of minocycline. Neurobiol Dis 25: 198-205.
23. Matassov D, Kagan T, Leblanc J, Sikorska M, Zakeri Z. 2004. Measurement of apoptosis by DNA fragmentation. Methods Mol Biol 282: 1-17.
24. NINDS NET-PD Investigators. 2008. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol 31: 141-150.
25. Orsucci D, Calsolaro V, Mancuso M, Siciliano G. 2009. Neuroprotective effects of tetracyclines: molecular targets, animal models and human disease. CNS Neurol Disord Drug Targets 8: 222-231.
26. Ossola B, Kääriäinen TM, Raasmaja A, Männistö PT. 2008. Time-dependent protective and harmful effects of quercetin on 6-OHDA-induced toxicity in neuronal SH-SY5Y cells. Toxicology 250: 1-8.
27. Pan T, Kondo S, Le W, Jankovic J. 2008. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 131: 1969-1978.
28. Pi R, Li W, Lee NT, Chan HH, Pu Y, Chan LN, Sucher NJ, Chang DC, Li M, Han Y. 2004. Minocycline prevents glutamate-induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways. JNeurochem 91: 1219-1230.
29. Puttonen KA, Manakova S, Raasmaja A, Mannisto PT. 2003. Increased p53 levels without caspase-3 activity and change of cell viability in 6-hydroxydopamine-treated CV1-P cells. Cell Biol Toxicol 19: 177-187.
30. Quintero EM, Willis L, Singleton R, Harris N, Huang P, Bhat N, Granholm AC. 2006. Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson's disease. Brain Res 1093: 198-207.
31. +-exchanger leads to caspase-independent death of cerebellar granule neurons resembling paraptosis. Cell Death Differ 11: 760-770.
32. Sperandio S, de Belle I, Bredesen DE. 2000. An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci U S A 97: 14376-14381.
33. Sperandio S, Poksay KS, Schilling B, Crippen D, Gibson BW, Bredesen DE. 2010. Identification of new modulators and protein alterations in non-apoptotic programmed cell death. J Cell Biochem 111: 1401-1412.
34. Sriram K, Miller DB, O'Callaghan JP. 2006. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. JNeurochem 96: 706-718.
35. Stefanova N, Mitschnigg M, Ghorayeb I, Diguet E, Geser F, Tison F, Poewe W, Wenning GK. 2004. Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration. J Neurosci Res 78: 87-91.
36. Tikka TM, Koistinaho JE. 2001. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. JImmunol 166: 7527-7533.
37. Tomas-Camardiel M, Rite I, Herrera AJ, de Pablos RM, Cano J, Machado A, Venero JL. 2004. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol Dis 16: 190-201.
38. Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, Ferrante RJ, Kristal BS, Friedlander RM. 2003. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci U S A 100: 10483-10487.
39. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S. 2002. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22: 1763-1771.
40. Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, Browne SE, Shimizu Y, Joh TH, Beal MF, Albers DS. 2003. Minocycline enhances MPTP toxicity to dopaminergic neurons. J Neurosci Res 74: 278-285.
41. Yrjänheikki J, Keinänen R, Pellikka M, Hökfelt T, Koistinaho J. 1998. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 95: 15769-15774.
42. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu DC, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM. 2002. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417: 74-78.